NCT03284424 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 105
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 159
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG000
- title
- Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort
- description
- Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG001
- title
- Locally Advanced Unresectable cSCC Cohort
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 14.3
- value
- 70.0
- group Id
- BG001
- spread
- 12.4
- value
- 73.7
- group Id
- BG002
- spread
- 13.8
- value
- 71.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 40
- title
- Female
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 119
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 15
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 97
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 47
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 68
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 108
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 44
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The analysis population consisted of all participants who received ≥1 dose of study treatment.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 105
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 159
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG000
- title
- Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) Cohort
- description
- Participants received pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 doses (approximately 24 months). Eligible participants who stopped the initial course of pembrolizumab but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.
- id
- BG001
- title
- Locally Advanced Unresectable cSCC Cohort
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 14.3
- value
- 70.0
- group Id
- BG001
- spread
- 12.4
- value
- 73.7
- group Id
- BG002
- spread
- 13.8
- value
- 71.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 40
- title
- Female
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 119
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 15
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 97
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 47
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 68
- group Id
- BG001
- value
- 40
- group Id
- BG002
- value
- 108
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 44
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The analysis population consisted of all participants who received ≥1 dose of study treatment.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle